Abstract:Objective To explore the clinical value of matrix metalloproteinase(MMPs)antibody chip in the diagnosis of gastric cancer(GC). Methods Serum samples from 12 patients with gastric cancer (GC)and 10 patients with non?neoplastic gastric disease(NGD)diagnosed in our hospital from November 2016 to March 2017 were collected to form a training set. Human MMP arrays were used to quantitative measurement of 7 major secretory MMPs and 3 tissue inhibitors of metalloproteinases (TIMPs) simultaneously in the above patients. Their concentration differences between GC and NGD groups and their diagnostic efficacy for GC were compared. The MMP subtypes with the greatest concentration difference between the two groups were screened for further study. Serum samples from 40 patients with GC and 38 patients with NGD diagnosed in our hospital from April 2017 to July 2017 were collected to form a validation set. The concentration of TIMP?4 in serum of these patients was detected by suspension microbead chip. Then the levels of TIMP?4 was compared between the GC and NGD groups and its diagnostic value was assessed by ROC curve. Results The MMP subtypes with high expression(>10 000 pg/ml)in the training set included:MMP?1,MMP?3,MMP?9 and TIMP?1;medium expression(1 000?10 000 pg/ml):MMP?8,TIMP?2 and TIMP?4;low expression(<1 000 pg/ml):MMP?2,MMP?10 and MMP?13. Compared with the NGD group, except MMP?2,MMP?3 and MMP?13,other MMPs showed an upward trend in the GC group,but no significant difference. Only TIMP?4 increased significantly in the GC group than NGD group(P<0.05). The area under the curve(AUC)of the MMP family members for the diagnosis of GC ranged from 0.500 to 0.858,and their combined AUC was 0.925(95%CI :0.782?1.000). Particularly,TIMP?4,whose AUC was the highest,was 0.858 (95%CI :0.692?1.000). At the optimal cut?off value of 2 438.3 pg/ml,its sensitivity,specificity and Yoden index for the diagnosis of GC were 83.3%,80% and 0.633,respectively. In the validation set,the concentrations of TIMP?4 in the GC and NGD groups were(1 148.0±691.5)pg/ml and (834.3 ± 397.2) pg/ml, respectively (P<0.05). Its AUC was 0.628 (95%CI : 0.498?0.758). Conclusions The detection of serum MMP expression profile is expected to be a new method for assistant diagnosis and screening of GC. TIMP?4 has certain reference value for the diagnosis of GC,but its diagnostic ability needs further verification.

Measurement of Urinary TIMP-2：a Possible Method to Diagnose Bladder Tumor

Quantitative detection of T1E4 mRNA-the isoform of fusion gene TMPRSS2:ERG in urine for the diagnosis of prostate cancer

Quantitative Detection of PCA3 mRNA and T1E4 mRNA-the Isoform of Fusion Gene TMPRSS2:ERG in Urine of Patients for the Early Clinical Diagnosis of Prostate Cancer

Prognostic Value of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 in Bladder Carcinoma.

Expression of Matrix Metalloproteinase-9 and Their Correlation with Tumor Invasion, Metastasis in Gastric Carcinoma

Microfluidic Assaying of Circulating Tumor Cells and its Correlation with Muscle Invasiveness and Tumor Grade of Urothelial Bladder Cancer

Clinical Research of MMP-2 and TIMP-2 Expression in Patients of Malignant Tumor

The Expression of Matrirx Metalloproteinase and Tissue Inhibitor of Metallo-proteinase in Endometrial Child Care

The expressions and significance of MMP-2 and TIMP-2 in human pancreatic carcinoma

Prognostic Significance of MMP-2 and TIMP-2 Expression in Infiltrating Breast Cancer

Expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in plasma of patients with colorectal carcinoma

The Clinical Significance of Determining Expressions of Urinary MMP-2,MMP-9 and MMP-9/NGAL Complex for Screening Patients with Breast Cancer in High-risk Female Population

Expression and Significance of MMP-2 and TIMP-2 in Human Colorectal Carcinoma and Its Metastasis

Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma

Studies on Urinary Nuclear Matrix Protein 22 Values in Patients with Transitional Cell Carcinoma of the Bladder

Research on Clinical Application Value of MMP Quantitative Array in Diagnosis of Gastric Cancer

Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients

Matrix Metalloproteinase 11 is a Potential Biomarker in Bladder Cancer Diagnosis and Prognosis

Expression and Clinical Significance of Matrix Metalloproteinase_(-2) and Its Tissue Inhibitor of Metalloproteinase_(-2) in Thyroid Cancer

Comparison of Tumor Markers in the Early Detection of Bladder Cancer